NCI’s use of Cancer Dialogue for biospecimen network blueprint raises legal, procedural questions.
Plan posted for “public comment” on Dialogue’s Web site; who will respond, Dialogue or NCI? Cost estimate of network significantly reduced.
Also Stillman named director, Cold Spring Harbor, Watson is chancellor.
Pollin Prize honors four pioneers in treatment of childhood leukemia.
December Business & Regulatory Report included in this issue.
The Cancer Letter takes two-week break; next issue Jan. 2.
Trending Stories
- NCI’s Letai, FDA’s Diamantas identify strategies to speed up cancer trials
Letai: 150 days to start a cancer trial is too long—cancer centers need to accept a little risk - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - ACS strengthens recommendation for prostate cancer screening
Many will hear the endorsement and ignore the limitations - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - CMS rule cuts overall oncology payments by estimated 2%
Final rule slashes 340B, moves toward site-neutrality - Kay “Taddy” Dickersin, NBCC co-founder, dies at 74









